🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are reported in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

As per findings detailed in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The trial included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to make available and distribute the drug in many developing nations.

Clinicians directly involved have expressed optimism. Having a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.